Healthcare Equipment and Supplies
Company Overview of OrbusNeich Medical Company Limited
OrbusNeich Medical Company Limited designs, develops, manufactures, and markets medical devices for the treatment of vascular diseases. The company offers dual therapy, bare metal, pro-healing, bio-engineered R, and bio-engineered cobalt chromium stents; and other stents and balloons. It serves interventional cardiologists and physicians in Hong Kong and internationally through its predecessor companies, sales teams, and a distributor network. The company was formerly known as Neich Medical Company Limited and changed its name to OrbusNeich Medical Company Limited following its merger with Orbus Medical Technologies, Inc. in January 2005. The company was founded in 1979 and is headquartered ...
39 Gloucester Road
Founded in 1979
Key Executives for OrbusNeich Medical Company Limited
Chief Executive Officer, President and Director
Chairman of The Board and Executive in Charge of Asia Pacific
Founder, Chairman Emeritus and Director
Chief Financial Officer, Vice President and Director
Senior Vice President of Global Operation and Director
Compensation as of Fiscal Year 2016.
OrbusNeich Medical Company Limited Key Developments
OrbusNeich Announces Enrollment of First Patient in China Recovery Study
Jul 20 15
OrbusNeich has announced that the first patient has been enrolled in the clinical study in China of its COMBO™ Dual Therapy Stent. The China Recovery Study is designed to evaluate the COMBO Dual Therapy Stent compared to the Nano stent (Lepu Medical Technology Co, Ltd). The first patient was enrolled by Dr. Yuan Ming at The First Affiliated Hospital of the Fourth Military Medical University in May 2015. The study, a multi-center, prospective, non-inferiority, randomized controlled trial, will enroll 436 patients at up to 20 hospitals throughout China. The study will enroll patients with de novo stenotic lesions in native coronary arteries. Patients will be randomized 1:1 to the COMBO Dual Therapy Stent or the Nano stent, with follow up at 30 days, 6 months, 12 months and annually for up to 5 years. Additionally, Angiographic follow-up will be performed for all subjects at 9 months post-procedure. The principal investigator is Professor Tao Ling from the First Affiliated Hospital of the Fourth Military Medical University, Xian, China.
Orbusneich Appoints Ricky Kwan as Vice President, Asia Pacific Sales
May 29 15
OrbusNeich announced the appointment of Ricky Kwan to the role of Vice President, Asia Pacific Sales. With an outstanding 22-year career in medical sales and product management, having served most recently as Program Director at Biotronik, Mr. Kwan possesses vast experience in cardiovascular device sales management. Mr. Kwan will be based in Singapore and will report directly to Alain Aimonetti, Senior Vice President, Global Sales and Marketing.
OrbusNeich Appoints Alain Aimonetti as Vice President Global Marketing and Sales EMEA
Mar 2 15
OrbusNeich announced the appointment of Alain Aimonetti as Vice President Global Marketing and Sales EMEA. Mr. Aimonetti will focus on the company's extensive portfolio of high-performance stents and balloons, including the COMBOTM Dual Therapy Stent - the world's first dual therapy stent, launched in 2013. His most recent position was at Biotronik where he was VP Global Sales and Business Development, Vascular Intervention.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|